Skip to main content

Ogivri News

Adjuvant Trastuzumab Emtansine Improves Overall Survival in HER2+ Breast Cancer

THURSDAY, Jan. 16, 2025 – For patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, adjuvant trastuzumab emtansine (T-DM1) improves overall survival more than...

FDA Approves Kanjinti (trastuzumab-anns), a Biosimilar to Herceptin

THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ – Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Kanjinti...

FDA Approves Ogivri (trastuzumab-dkst), a Biosimilar to Herceptin

December 1, 2017 – The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Breast Cancer - Adjuvant, Breast Cancer, Metastatic, Breast Cancer, Gastric Cancer

Ogivri patient information at Drugs.com